Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy

Khan, S., Lutzky, J., Shoushtari, A. N., Jeter, J., Marr, B., Olencki, T. E., Cebulla, C. M., Abdel-Rahman, M., Harbour, J. W., Sender, N., Nesson, A., Singh-Kandah, S., Hernandez, S., King, J., Katari, M. S., Dimapanat, L., Izard, S., Ambrosini, G., Surriga, O., … Carvajal, R. D. (2022). Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.976837
Authors:
Shaheer Khan
Jose Lutzky
Alexander N. Shoushtari
Joanne Jeter
Brian P. Marr
Thomas Olencki
Colleen M. Cebulla
Mohamed Abdel-Rahman
J. William Harbour
Naomi Sender
Alexandra Nesson
Shahnaz Singh-Kandah
Susana Hernandez
Jeanelle King
Manpreet S. Katari
Lyssa Dimapanat
Stephanie Izard
Grazia Ambrosini
Oliver Surriga
J. Alex
Codruța Chiuzan
Gary K. Schwartz
Richard D. Carvajal
Affiliated Authors:
Shaheer Khan
Brian P. Marr
Naomi Sender
Alexandra Nesson
Shahnaz Singh-Kandah
Susana Hernandez
Lyssa Dimapanat
Grazia Ambrosini
Oliver Surriga
J. Alex
Gary K. Schwartz
Richard D. Carvajal
Columbia Affiliation:
Subjects:
Ocular Cancer Research and Treatment (OpenAlex Topic)
Ear and Head Tumors (OpenAlex Topic)
Immunobiology of Dendritic Cells (OpenAlex Topic)
Author Keywords:
uveal melanoma
high-risk
adjuvant therapy
crizotinib
extracellular vesicles
elink
Publication Type:
Article
Unique ID:
10.3389/fonc.2022.976837
PMID:
36106113
DOI:
10.3389/fonc.2022.976837
Journal:
Frontiers in Oncology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View Web of Science Record

Record Created: